Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 203-210

  Hall, W Dallas ^a,f   Montoro, Rafael ^b   Littlejohn, Thomas ^c   Jain, Adesh ^d   Feliciano, Nancy ^e   Zheng, Hongjie ^e  

^a Hypertension Research Center   (United States)

^b Clinical Therapeutics Corp   (United States)

^c Piedmont Medical Research Associates   (United States)

^d General Clinical Research Center New Orleans   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Hypertension Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0031720474     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00004     Document Type: Article

References (18)

1. 1 receptor subtype. Br J Pharmacol 1993; 110: 761-71
2. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810
3. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-51
4. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341-6
5. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52 (3): 173-7
6. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-7
7. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 1997; 157: 2413-46
8. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969-78
9. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
10. Maillon J-M, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist: efficacy and tolerability compared with an angiotensin converting enzyme inhibitor enalapril in essential hypertension. Blood Press Monitor 1997; 2: 179-85
11. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979; 25: 33-9
12. Frishman WH, Goldberger J, Sherman D. Enalapril, hydrocholorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens 1987; 3: 520-7
13. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150: 1175-83
14. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-85
15. Gavras HP, Salerno CM. The angiotensin II type I receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18: 1058-68
16. 1993 Guidelines fur the management of mild hypertension: memorandum from WHO/ISH meeting. Clin Exp Hypertens 1993; 15 (6): 1363-95
17. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Human Hypertens 1997; 11: 483-9
18. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995 Jul; 26: 112-7